急性肾损伤后蛋白尿与后续肾病进展:ASSESS-AKI研究
ASSESS-AKI研究为多中心前瞻性队列研究,纳入北美4个临床中心1538例患者,于出院后3个月入组。其中769例(50%)住院期间发生急性肾损伤。中位随访4.7年后,138例(9%)出现肾病进展。急性肾损伤后尿白蛋白肌酐比值每翻倍,肾病进展风险增加(HR 1.53,95%CI 1.45-1.62),且尿白蛋白肌酐比值对未来肾病进展有强判别力(C统计量0.82)。在校正尿白蛋白肌酐比值、eGFR、人口学特征和传统慢性肾脏病危险因素后,急性肾损伤本身或严重程度与肾病进展无独立关联。作者认为急性肾损伤后蛋白尿水平是有价值的风险分层工具,建议更广泛、常规地定量检测住院急性肾损伤后的蛋白尿。
要点
- 住院期间发生急性肾损伤的患者,出院后3个月尿白蛋白肌酐比值每翻倍,后续肾病进展风险增加(HR 1.53,95%CI 1.45-1.62)。
- 尿白蛋白肌酐比值对未来肾病进展判别力强(C统计量0.82),在曾发生急性肾损伤的患者中优于未发生者(C统计量0.70)。
- 包含eGFR、血压、人口学特征和尿白蛋白肌酐比值的综合模型,在急性肾损伤患者中判别力C统计量0.85,优于未发生急性肾损伤者0.76。
- 校正尿白蛋白肌酐比值、eGFR、人口学特征和传统慢性肾脏病危险因素后,急性肾损伤(HR 1.46,95%CI 0.51-4.13)或急性肾损伤严重程度与肾病进展无独立关联。
- 作者认为急性肾损伤后蛋白尿水平是有价值的风险分层工具,建议更广泛、常规地定量检测住院急性肾损伤后的蛋白尿。
适用人群与场景
- 纳入标准:住院期间发生急性肾损伤或未发生急性肾损伤的成人患者,于出院后3个月入组;共1538例,其中769例(50%)住院期间发生急性肾损伤。
- 场景:出院后随访阶段,非急诊或ICU床旁急性期。
诊断标准与关键阈值
- 肾病进展定义:估计肾小球滤过率减半或终末期肾病。
- 尿白蛋白肌酐比值于出院后3个月定量检测(平均91天,标准差23天)。
研究设计与关键结果
- 研究设计:多中心前瞻性队列研究,北美4个临床中心,纳入1538例患者,2009年12月至2015年2月出院后3个月入组。
- 人群特征:平均年龄65岁(标准差13),中位eGFR 68 mL/min/1.73 m2,中位尿白蛋白肌酐比值15 mg/g;547例(37%)为女性,195例(13%)为黑人。
- 主要终点:中位随访4.7年,138例(9%)出现肾病进展。
- 急性肾损伤后尿白蛋白肌酐比值每翻倍,肾病进展风险增加(HR 1.53,95%CI 1.45-1.62);尿白蛋白肌酐比值判别力C统计量0.82,在曾发生急性肾损伤者中C统计量0.70,优于未发生者。
- 综合模型(eGFR、血压、人口学特征加尿白蛋白肌酐比值)在急性肾损伤患者中判别力C统计量0.85,优于未发生急性肾损伤者0.76。
- 校正尿白蛋白肌酐比值、eGFR、人口学特征和传统慢性肾脏病危险因素后,急性肾损伤与肾病进展无独立关联(HR 1.46,95%CI 0.51-4.13,急性肾损伤 vs 非急性肾损伤);急性肾损伤严重程度亦无独立关联(1期 vs 非急性肾损伤:HR 1.54,95%CI 0.50-4.72;2期 vs 非急性肾损伤:HR 0.56,95%CI 0.07-4.84;3期 vs 非急性肾损伤:HR 2.24,95%CI 0.33-15.29)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为急性肾损伤后蛋白尿水平是有价值的风险分层工具,建议更广泛、常规地定量检测住院急性肾损伤后的蛋白尿。
- 对住院期间发生急性肾损伤的患者,出院后3个月检测尿白蛋白肌酐比值有助于识别后续肾功能丧失高风险者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Among patients who had acute kidney injury (AKI) during hospitalization, there is a need to improve risk prediction such that those at highest risk for subsequent loss of kidney function are identified for appropriate follow-up.
OBJECTIVE: To evaluate the association of post-AKI proteinuria with increased risk of future loss of renal function.
DESIGN, SETTING, AND PARTICIPANTS: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study was a multicenter prospective cohort study including 4 clinical centers in North America included 1538 patients enrolled 3 months after hospital discharge between December 2009 and February 2015.
EXPOSURES: Urine albumin-to-creatinine ratio (ACR) quantified 3 months after hospital discharge.
MAIN OUTCOMES AND MEASURES: Kidney disease progression defined as halving of estimated glomerular filtration rate (eGFR) or end-stage renal disease.
RESULTS: Of the 1538 participants, 769 (50%) had AKI durring hospitalization. The baseline study visit took place at a mean (SD) 91 (23) days after discharge. The mean (SD) age was 65 (13) years; the median eGFR was 68 mL/min/1.73 m2; and the median urine ACR was 15 mg/g. Overall, 547 (37%) study participants were women and 195 (13%) were black. After a median follow-up of 4.7 years, 138 (9%) participants had kidney disease progression. Higher post-AKI urine ACR level was associated with increased risk of kidney disease progression (hazard ratio [HR], 1.53 for each doubling; 95% CI, 1.45-1.62), and urine ACR measurement was a strong discriminator for future kidney disease progression (C statistic, 0.82). The performance of urine ACR was stronger in patients who had had AKI than in those who had not (C statistic, 0.70). A comprehensive model of clinical risk factors (eGFR, blood pressure, and demographics) including ACR provided better discrimination for predicting kidney disease progression after hospital discharge among those who had had AKI (C statistic, 0.85) vs those who had not (C statistic, 0.76). In the entire matched cohort, after taking into account urine ACR, eGFR, demographics, and traditional chronic kidney risk factors determined 3 months after discharge, AKI (HR, 1.46; 95% CI, 0.51-4.13 for AKI vs non-AKI) or severity of AKI (HR, 1.54; 95% CI, 0.50-4.72 for AKI stage 1 vs non-AKI; HR, 0.56; 95% CI, 0.07-4.84 for AKI stage 2 vs non-AKI; HR, 2.24; 95% CI, 0.33-15.29 for AKI stage 3 vs non-AKI) was not independently associated with more rapid kidney disease progression.
CONCLUSIONS AND RELEVANCE: Proteinuria level is a valuable risk-stratification tool in the post-AKI period. These results suggest there should be more widespread and routine quantification of proteinuria after hospitalized AKI.
参考来源
- Hsu CY, Chinchilli VM, Coca S, et al. Post-Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. JAMA Intern Med. 2020. PMID: 31985750. doi:10.1001/jamainternmed.2019.6390
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。